Active	Status	Sponsor type	Region	Phase	Filter
9 Active 1 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Frazier, Patrick
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
NCT04524962: Study of Descartes-30 in Acute Respiratory Distress Syndrome	Terminated	1	12	US	Descartes 30	Cartesian Therapeutics, National Heart, Lung, and Blood Institute (NHLBI)	Acute Respiratory Distress Syndrome, Covid19	09/22	09/23
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial	Recruiting	N/A	1247	Europe, Canada, US	Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System	Edwards Lifesciences	Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation	06/26	06/31
NCT05844280: The Role of Blood Flow Restriction Therapy in Postop Rehabilitation of Foot and Ankle Injuries	Withdrawn	N/A	28	NA	BFR+NMES at therapeutic level, BFR+NMES at sub therapeutic level	University of Alabama at Birmingham	Fracture of Foot	08/28	12/29
Schotta, Collin
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
Sanford, Haley
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Frazier, Patrick
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
NCT04524962: Study of Descartes-30 in Acute Respiratory Distress Syndrome	Terminated	1	12	US	Descartes 30	Cartesian Therapeutics, National Heart, Lung, and Blood Institute (NHLBI)	Acute Respiratory Distress Syndrome, Covid19	09/22	09/23
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial	Recruiting	N/A	1247	Europe, Canada, US	Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System	Edwards Lifesciences	Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation	06/26	06/31
NCT05844280: The Role of Blood Flow Restriction Therapy in Postop Rehabilitation of Foot and Ankle Injuries	Withdrawn	N/A	28	NA	BFR+NMES at therapeutic level, BFR+NMES at sub therapeutic level	University of Alabama at Birmingham	Fracture of Foot	08/28	12/29
Schotta, Collin
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
Sanford, Haley
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25